A Phase 3 interventional study of Ramucirumab and Placebo in Colorectal Cancer, sponsored by Eli Lilly and Company. Completed at 213 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Colorectal Neoplasms by Eli Lilly and Company — 4 open to participants now, 7 under way, none of them phase 3. Colorectal Neoplasms · Eli Lilly and Company.
Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, this one is the 2nd largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2010, is one of 3 in phase 3, and was the 20th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →4 of the 37 studies in Colorectal Neoplasms by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, China, Germany and 2 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, China, Spain
Ages 18+
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 19 · Phase 3 3
First in 2002; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,072 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 103 across the 34 interventional studies. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Colorectal Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Colorectal Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Ramucirumab · Drug: Irinotecan · Drug: Folinic Acid · Drug: 5-Fluorouracil
Biological: Placebo · Drug: Irinotecan · Drug: Folinic Acid · Drug: 5-Fluorouracil
8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Also known as: LY3009806, IMC-1121B
Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
180 milligrams/square meter (mg/m\^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
400 mg/m\^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Also known as: leucovorin
400 mg/m\^2 bolus immediately followed by 2400 mg/m\^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Overall Survival (OS)
OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive.
Time frame: Randomization to Date of Death from Any Cause Up to 39.36 Months
Progression-free Survival (PFS) Time
PFS was defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) \[according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1\] or death due to any cause, whichever was first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment.
Time frame: Randomization to Measured PD or Date of Death from Any Cause Up to 38.01 Months
Percentage of Participants Achieving an Objective Response (Objective Response Rate)
The objective response rate is equal to the proportion of participants achieving a best overall response of partial response or complete response (PR + CR). Response was defined using RECIST, v. 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameter.
Time frame: Randomization until Disease Progression Up to 38.01 Months
Change From Baseline in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Global Health Status
The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Maximum improvement is the best post-baseline change.
Time frame: Baseline Up to 171 Weeks
Change From Baseline in EuroQol- 5D (EQ-5D)
The EQ-5D is a generic, multidimensional, health status instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status.
Time frame: Baseline and 30-Day Follow-Up (FU) up to 171 Weeks
Percentage of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies
Blood samples were tested to determine if a participant reacted to ramucirumab by producing anti-ramucirumab antibodies. Samples were identified as treatment emergent anti-drug antibody (TE ADA) if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)\*100.
Time frame: Cycles 1, 3, 5, and 30-Day FU
Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab
Time frame: Preinfusion and 1 hour postinfusion in Cycles 3, 5, 9, 13, and 17
| Milestone | Ramucirumab + FOLFIRI | Placebo + FOLFIRI |
|---|---|---|
| Started | 536 | 536 |
| Received at least 1 dose of study drug | 528 | 529 |
| Completed | 505 | 511 |
| Not completed | 31 | 25 |
| Withdrew: Withdrawal by subject | 25 | 14 |
| Withdrew: Lost to follow-up | 6 | 11 |
OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive.
| months | Ramucirumab + FOLFIRI | Placebo + FOLFIRI |
|---|---|---|
| Overall Survival (OS) | 13.3 (12.4 to 14.5) | 11.7 (10.8 to 12.7) |
PFS was defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) \[according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1\] or death due to any cause, whichever was first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment.
| months | Ramucirumab + FOLFIRI | Placebo + FOLFIRI |
|---|---|---|
| Progression-free Survival (PFS) Time | 5.7 (5.5 to 6.2) | 4.5 (4.2 to 5.4) |
The objective response rate is equal to the proportion of participants achieving a best overall response of partial response or complete response (PR + CR). Response was defined using RECIST, v. 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameter.
| percentage of participants | Ramucirumab + FOLFIRI | Placebo + FOLFIRI |
|---|---|---|
| Percentage of Participants Achieving an Objective Response (Objective Response Rate) | 13.4 (10.7 to 16.6) | 12.5 (9.8 to 15.6) |
The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Maximum improvement is the best post-baseline change.
| units on a scale | Ramucirumab + FOLFIRI | Placebo + FOLFIRI |
|---|---|---|
| Change From Baseline in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Global Health Status | 4.0 ± 20.61 | 6.6 ± 18.84 |
The EQ-5D is a generic, multidimensional, health status instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status.
| units on a scale | Ramucirumab + FOLFIRI | Placebo + FOLFIRI |
|---|---|---|
| Change From Baseline in EuroQol- 5D (EQ-5D) | -0.097 ± 0.279 | -0.103 ± 0.264 |
Blood samples were tested to determine if a participant reacted to ramucirumab by producing anti-ramucirumab antibodies. Samples were identified as treatment emergent anti-drug antibody (TE ADA) if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)\*100.
| percentage of participants | Ramucirumab + FOLFIRI | Placebo + FOLFIRI |
|---|---|---|
| Immunogenicity Any Time During Study (n=516, 512) | 5.6 | 5.5 |
| Immunogenicity Post-Treatment (n=477, 473) | 3.1 | 3.8 |
| micrograms/milliliter (ug/mL) | Ramucirumab + FOLFIRI |
|---|---|
| Cmin Dose 3 (n=248) | 46.3 ± 45.0 |
| Cmin Dose 5 (n=154) | 65.1 ± 43.0 |
| Cmin Dose 9 (n=27) | 77.9 ± 51.0 |
| Cmin Dose 13 (n=11) | 75.9 ± 43.0 |
| Cmin Dose 17 (n=5) | 72.0 ± 49.0 |
| Cmax Dose 3 (n=88) | 221.0 ± 37.0 |
| Cmax Dose 5 (n=51) | 243.0 ± 39.0 |
| Cmax Dose 9 (n=18) | 262.0 ± 36.0 |
| Cmax Dose 13 (n=12) | 307.0 ± 33.0 |
| Cmax Dose 17 (n=7) | 253.0 ± 19.0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FOLFIRI + Ramucirumab | — | 198/529 (37.4%) | 518/529 (97.9%) |
| FOLFIRI + Placebo | — | 175/528 (33.1%) | 510/528 (96.6%) |
| Event | FOLFIRI + Ramucirumab | FOLFIRI + Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 19/529 | 18/528 |
| Febrile neutropeniaBlood and lymphatic system disorders | 15/529 | 8/528 |
| Abdominal painGastrointestinal disorders | 10/529 | 14/528 |
| VomitingGastrointestinal disorders | 13/529 | 6/528 |
| Intestinal obstructionGastrointestinal disorders | 8/529 | 11/528 |
| SepsisInfections and infestations | 5/529 | 11/528 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 10/529 | 6/528 |
| PyrexiaGeneral disorders | 4/529 | 8/528 |
| NauseaGastrointestinal disorders | 8/529 | 6/528 |
| PneumoniaInfections and infestations | 7/529 | 7/528 |
| Event | FOLFIRI + Ramucirumab | FOLFIRI + Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 315/529 | 271/528 |
| NauseaGastrointestinal disorders | 265/529 | 274/528 |
| FatigueGeneral disorders | 254/529 | 225/528 |
| Decreased appetiteMetabolism and nutrition disorders | 203/529 | 149/528 |
| NeutropeniaBlood and lymphatic system disorders | 183/529 | 131/528 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 182/529 | 80/528 |
| AlopeciaSkin and subcutaneous tissue disorders | 156/529 | 168/528 |
| StomatitisGastrointestinal disorders | 166/529 | 113/528 |
| ConstipationGastrointestinal disorders | 157/529 | 132/528 |
| VomitingGastrointestinal disorders | 151/529 | 143/528 |
All randomized participants.
| Age, Categorical(Participants) | Ramucirumab + FOLFIRI | Placebo + FOLFIRI | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 324 | 321 | 645 |
| >=65 years | 212 | 215 | 427 |
| Age, Continuous(years) | Ramucirumab + FOLFIRI | Placebo + FOLFIRI | Total |
|---|---|---|---|
| Median | 62.0 (21.0 to 83.0) | 62.0 (33.0 to 87.0) | 62.0 (21.0 to 87.0) |
| Sex: Female, Male(Participants) | Ramucirumab + FOLFIRI | Placebo + FOLFIRI | Total |
|---|---|---|---|
| Female | 247 | 210 | 457 |
| Male | 289 | 326 | 615 |
| Ethnicity (NIH/OMB)(Participants) | Ramucirumab + FOLFIRI | Placebo + FOLFIRI | Total |
|---|---|---|---|
| Hispanic or Latino | 38 | 39 | 77 |
| Not Hispanic or Latino | 248 | 221 | 469 |
| Unknown or Not Reported | 250 | 276 | 526 |
| Race (NIH/OMB)(Participants) | Ramucirumab + FOLFIRI | Placebo + FOLFIRI | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 111 | 103 | 214 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 14 | 16 | 30 |
| White | 405 | 410 | 815 |
| More than one race | 3 | 0 | 3 |
| Unknown or Not Reported | 2 | 5 | 7 |
| Region of Enrollment(Participants) | Ramucirumab + FOLFIRI | Placebo + FOLFIRI | Total |
|---|---|---|---|
| United States | 141 | 142 | 283 |
| Portugal | 2 | 2 | 4 |
| Taiwan | 5 | 6 | 11 |
| Greece | 8 | 8 | 16 |
| Spain | 51 | 60 | 111 |
| Israel | 7 | 7 | 14 |
| Italy | 17 | 20 | 37 |
| India | 1 | 2 | 3 |
| France | 12 | 15 | 27 |
| Puerto Rico | 2 | 1 | 3 |
| Australia | 16 | 19 | 35 |
| Denmark | 3 | 8 | 11 |
| Netherlands | 9 | 5 | 14 |
| Korea, Republic of | 22 | 25 | 47 |
| Finland | 9 | 3 | 12 |
| Austria | 6 | 12 | 18 |
| Czech Republic | 40 | 37 | 77 |
| Hungary | 24 | 23 | 47 |
| Argentina | 7 | 11 | 18 |
| Belgium | 30 | 22 | 52 |
| Brazil | 2 | 3 | 5 |
| Romania | 19 | 14 | 33 |
| Germany | 19 | 25 | 44 |
| Japan | 74 | 62 | 136 |
| Sweden | 10 | 4 | 14 |
Showing the first 100 of 213 sites across 26 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2010 to primary completion in Jul 2014, 43 months.
Results were first posted in Jul 2015, 11 months after primary completion.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 43 months is close to that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab